Department of Oral and Maxillofacial Surgery, "Carol Davila" Central Military Emergency Hospital, 010825 Bucharest, Romania.
Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, "Titu Maiorescu" University, 031593 Bucharest, Romania.
Medicina (Kaunas). 2022 Jun 30;58(7):874. doi: 10.3390/medicina58070874.
During the last two years, the COVID-19 pandemic led to millions of disease-related deaths worldwide. The efforts of the scientific community facing this global challenge resulted in outstanding achievements. Thus, within one year, new mRNA-based vaccines against SARS-CoV-2 viral infection were released, providing highly efficient protection and showing a very good safety profile in the general population. However, clinical data collection after vaccination is a continuous process for the long-term safety of any new medical product. The aim of our paper is to present two cases of hematological malignancies: diffuse large B-cell non-Hodgkin lymphoma and T/NK-cell lymphoma, diagnosed shortly after the administration of the mRNA COVID-19 vaccine.
Case 1: A female patient was admitted with a suspicious cervical mass that emerged within one week after the administration of second dose of the BNT162b2 COVID-19 vaccine. Surgical removal followed by pathology assessment of the specimen confirmed the diagnosis of diffuse large B-cell non-Hodgkin lymphoma. Case 2: A male patient was admitted with multiple ulcerative oral lesions arising on the third day after the initial dose of the BNT162b2 COVID-19 vaccine. These lesions had a progressive character and during the following months were complicated with repetitive episodes of heavy oral bleeding, requiring blood transfusions. The incisional biopsy of the lesions and pathological assessment of the specimens confirmed the diagnosis of T/NK-cell lymphoma.
The safety profile of the mRNA-based vaccines is an undeniable fact. In most cases, suspicions of potentially aggressive side effects were ruled out, proving to be transient post-vaccine reactions. Clinicians should remain alert to report any potentially aggressive manifestations emerging in the context of mRNA COVID-19 vaccination, such as these cases of hematological malignancies, in order to promote additional investigations on the particular mechanisms of action of COVID-19 vaccines and to provide the best medical care to the patients.
在过去的两年中，COVID-19 大流行导致了全球数百万人与疾病相关的死亡。科学界应对这一全球挑战的努力取得了杰出的成就。因此，在一年内，针对 SARS-CoV-2 病毒感染的新型基于 mRNA 的疫苗被推出，为普通人群提供了高效的保护，并表现出非常好的安全性。然而，疫苗接种后的临床数据收集是任何新医疗产品长期安全性的持续过程。我们的论文旨在介绍两例血液病恶性肿瘤病例：弥漫性大 B 细胞非霍奇金淋巴瘤和 T/NK 细胞淋巴瘤，这些病例在接种 mRNA COVID-19 疫苗后不久被诊断出来。
病例 1：一名女性患者因颈部可疑肿块入院，肿块在接种第二剂 BNT162b2 COVID-19 疫苗后一周内出现。手术切除后对标本进行病理评估，确诊为弥漫性大 B 细胞非霍奇金淋巴瘤。病例 2：一名男性患者因接种 BNT162b2 COVID-19 疫苗初始剂量后第三天出现多处溃疡性口腔病变而入院。这些病变具有进行性特征，在接下来的几个月中，反复出现严重的口腔出血，需要输血。对病变进行的切开活检和标本的病理评估，确诊为 T/NK 细胞淋巴瘤。
基于 mRNA 的疫苗的安全性是一个不可否认的事实。在大多数情况下，排除了潜在侵袭性副作用的怀疑，证明是疫苗接种后的短暂反应。临床医生应保持警惕，报告在 mRNA COVID-19 疫苗接种背景下出现的任何潜在侵袭性表现，如这些血液病恶性肿瘤病例，以促进对 COVID-19 疫苗特定作用机制的进一步研究，并为患者提供最佳的医疗护理。
